Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
LJPC Stock Summary
In the News
La Jolla Pharmaceutical Company (LJPC) Stock: Why It Skyrocketed Over 80% Today
The stock price of La Jolla Pharmaceutical Company (NASDAQ: LJPC) surged by over 80% during intraday trading today. This is why.
Moving Average Crossover Alert: La Jolla Pharmaceutical (LJPC)
La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
WALTHAM, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress. Corporate Progress Operating Cash Flow Improved: La Jolla's net cash provided by (used for) operating activities for the three months ended March
La Jolla Pharmaceutical (LJPC) Reports Q4 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 62.86% and 7.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
La Jolla Pharma (LJPC) Sees Hammer Chart Pattern: Time to Buy?
La Jolla Pharmaceutical Company (LJPC) has been struggling lately, but the selling pressure may be coming to an end soon.
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2020
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2020. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. (Tetraphase), a biopharmaceutical company focused on commercializing its novel tetra
Regardless Of Who Wins The White House, This FTSE 100 Stock Could Benefit
Shares Analysis by Investing.com (Tezcan Gecgil/Investing.com) covering: FTSE 100, CRH PLC, Ashtead Group PLC, Vulcan Materials Company. Read Investing.com (Tezcan Gecgil/Investing.com)'s latest article on Investing.com UK.
PNC Financial Services Group Inc. Sells 3,271 Shares of Crh Plc (NYSE:CRH)
PNC Financial Services Group Inc. lessened its stake in Crh Plc (NYSE:CRH) by 26.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,007 shares of the construction company’s stock after selling 3,271 shares during the period. PNC Financial Services Group Inc.’s holdings in CRH […]
LJPC Financial details
LJPC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.4 | 0.85 | 1.22 | 2.22 | |
Net income per share | -5.41 | -7.85 | -4.3 | -1.44 | 0.58 | |
Operating cash flow per share | -4 | -5.99 | -3.13 | -1.38 | 0.83 | |
Free cash flow per share | -4.43 | -6.09 | -3.16 | -1.38 | 0.83 | |
Cash per share | 4.29 | 6.79 | 3.24 | 0.78 | 1.37 | |
Book value per share | 4.16 | 1.41 | -2.07 | -3.22 | -1.95 | |
Tangible book value per share | 4.16 | 1.41 | -2.07 | -4.5 | -2.93 | |
Share holders equity per share | 4.16 | 1.41 | -2.07 | -3.22 | -1.95 | |
Interest debt per share | 0 | 0.29 | 1.48 | 0.39 | 0.38 | |
Market cap | 682.7M | 239.73M | 106.55M | 106.04M | 158.93M | |
Enterprise value | 591.78M | 67.13M | 47.98M | 85.35M | 114.91M | |
P/E ratio | -5.95 | -1.2 | -0.91 | -2.69 | 8.08 | |
Price to sales ratio | 0 | 23.84 | 4.62 | 3.17 | 2.1 | |
POCF ratio | -8.04 | -1.57 | -1.25 | -2.82 | 5.63 | |
PFCF ratio | -7.26 | -1.55 | -1.24 | -2.82 | 5.63 | |
P/B Ratio | 7.74 | 6.67 | -1.9 | -1.2 | -2.38 | |
PTB ratio | 7.74 | 6.67 | -1.9 | -1.2 | -2.38 | |
EV to sales | 0 | 6.68 | 2.08 | 2.55 | 1.52 | |
Enterprise value over EBITDA | -5.21 | -0.36 | -0.47 | -3.38 | 3.59 | |
EV to operating cash flow | -6.97 | -0.44 | -0.56 | -2.27 | 4.07 | |
EV to free cash flow | -6.29 | -0.43 | -0.56 | -2.27 | 4.07 | |
Earnings yield | -0.17 | -0.83 | -1.09 | -0.37 | 0.12 | |
Free cash flow yield | -0.14 | -0.65 | -0.8 | -0.35 | 0.18 | |
Debt to equity | 0 | 0 | -0.52 | -0.01 | -0.04 | |
Debt to assets | 0 | 0 | 0.22 | 0.01 | 0.03 | |
Net debt to EBITDA | 0.8 | 0.92 | 0.58 | 0.82 | -1.37 | |
Current ratio | 5.07 | 5.95 | 3.96 | 2.95 | 3.82 | |
Interest coverage | 0 | -26.57 | -10.19 | -3.57 | 2.88 | |
Income quality | 0.74 | 0.76 | 0.73 | 0.95 | 1.44 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 6.09 | 1.65 | 1.03 | 0.39 | |
Research and developement to revenue | 0 | 11.66 | 3.7 | 0.69 | 0.07 | |
Intangibles to total assets | 0 | 0 | 0 | 0.48 | 0.33 | |
Capex to operating cash flow | 0.11 | 0.02 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | -0.23 | -0.03 | 0 | 0 | |
Capex to depreciation | -7.25 | -0.53 | -0.15 | 0 | 0 | |
Stock based compensation to revenue | 0 | 3.5 | 1.03 | 0.19 | 0.06 | |
Graham number | 22.5 | 15.79 | 14.13 | 10.23 | 5.03 | |
ROIC | -1.32 | -5.45 | -45.38 | 0.48 | -0.47 | |
Return on tangible assets | -0.96 | -0.98 | -0.88 | -1.06 | 0.29 | |
Graham Net | 2.81 | 0.25 | -3.58 | -4.82 | -3.19 | |
Working capital | 75.51M | 150.68M | 72.87M | 24.12M | 49.68M | |
Tangible asset value | 88.2M | 35.92M | -55.99M | -123.08M | -100.18M | |
Net current asset value | 62.73M | 12.75M | -90.78M | -123.87M | -100.65M | |
Invested capital | 0 | 0 | -0.52 | -0.01 | -0.04 | |
Average receivables | 0 | 690.5K | 2.17M | 4.4M | 8.91M | |
Average payables | 9.07M | 10.03M | 6.37M | 3.47M | 2.52M | |
Average inventory | 0 | 1.01M | 2.12M | 4.11M | 6.15M | |
Days sales outstanding | 0 | 50.13 | 46.86 | 63.72 | 57.77 | |
Days payables outstanding | 0 | 1.9K | 637.38 | 128.93 | 61.64 | |
Days of inventory on hand | 0 | 448.75 | 337.38 | 280.69 | 169.96 | |
Receivables turnover | 0 | 7.28 | 7.79 | 5.73 | 6.32 | |
Payables turnover | 0 | 0.19 | 0.57 | 2.83 | 5.92 | |
Inventory turnover | 0 | 0.81 | 1.08 | 1.3 | 2.15 | |
ROE | -1.3 | -5.55 | 2.08 | 0.45 | -0.29 | |
Capex per share | -0.43 | -0.09 | -0.03 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.58 | 0.48 | 0.44 | 0.32 | 0.33 | |
Net income per share | 0.14 | -0.08 | 0.05 | 0 | 0.08 | |
Operating cash flow per share | 0.26 | 0.03 | 0.12 | 0.08 | 0.21 | |
Free cash flow per share | 0.26 | 0.03 | 0.11 | 0.08 | 0.21 | |
Cash per share | 1.67 | 1.7 | 1.7 | 1.35 | 1.52 | |
Book value per share | -2.46 | -2.49 | -2.43 | -2.14 | -2.17 | |
Tangible book value per share | -3.7 | -3.72 | -3.64 | -3.15 | -3.18 | |
Share holders equity per share | -2.46 | -2.49 | -2.43 | -2.14 | -2.17 | |
Interest debt per share | 0.2 | 0.2 | 0.19 | 0.08 | 0.08 | |
Market cap | 117.53M | 109.71M | 127.86M | 140.55M | 102.34M | |
Enterprise value | 74.38M | 65.63M | 83.84M | 96.66M | 54.23M | |
P/E ratio | 7.87 | -12.14 | 24.2 | 17.57K | 10.41 | |
Price to sales ratio | 7.32 | 8.24 | 10.47 | 13.48 | 9.71 | |
POCF ratio | 16.47 | 143.23 | 40.41 | 55.75 | 15.32 | |
PFCF ratio | 16.47 | 143.23 | 40.53 | 55.75 | 15.32 | |
P/B Ratio | -1.74 | -1.6 | -1.92 | -1.99 | -1.47 | |
PTB ratio | -1.74 | -1.6 | -1.92 | -1.99 | -1.47 | |
EV to sales | 4.63 | 4.93 | 6.87 | 9.27 | 5.14 | |
Enterprise value over EBITDA | 10.79 | 67.8 | 12.55 | 33.78 | 10.32 | |
EV to operating cash flow | 10.42 | 85.68 | 26.5 | 38.34 | 8.12 | |
EV to free cash flow | 10.42 | 85.68 | 26.57 | 38.34 | 8.12 | |
Earnings yield | 0.03 | -0.02 | 0.01 | 0 | 0.02 | |
Free cash flow yield | 0.06 | 0.01 | 0.02 | 0.02 | 0.07 | |
Debt to equity | -0.04 | -0.04 | -0.04 | 0 | 0 | |
Debt to assets | 0.03 | 0.03 | 0.03 | 0 | 0 | |
Net debt to EBITDA | -6.26 | -45.54 | -6.59 | -15.34 | -9.16 | |
Current ratio | 4.05 | 4.12 | 3.82 | 3.92 | 4.02 | |
Interest coverage | 1.42 | 0.19 | 2.54 | 1 | 2.04 | |
Income quality | 1.91 | -0.34 | 0.84 | 1.26K | 2.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.48 | 0.53 | 0.61 | 0.86 | 0 | |
Research and developement to revenue | 0.07 | 0.1 | 0.09 | 0 | 0.01 | |
Intangibles to total assets | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -0.02 | 0 | 0 | |
Stock based compensation to revenue | 0.06 | 0.09 | 0.1 | 0.12 | 0.13 | |
Graham number | 2.74 | 2.14 | 1.62 | 0.05 | 1.93 | |
ROIC | -0.02 | -0.01 | -0.03 | -0.02 | -0.07 | |
Return on tangible assets | 0.06 | -0.03 | 0.02 | 0 | 0.04 | |
Graham Net | -4 | -3.99 | -3.97 | -3.4 | -3.48 | |
Working capital | 49.07M | 49.92M | 49.68M | 46.87M | 49.87M | |
Tangible asset value | -101.66M | -102.24M | -100.18M | -103.55M | -102.14M | |
Net current asset value | -102.29M | -102.79M | -100.65M | -103.95M | -102.47M | |
Invested capital | -0.04 | -0.04 | -0.04 | 0 | 0 | |
Average receivables | 9.75M | 12.07M | 12.08M | 10.54M | 7.52M | |
Average payables | 1.47M | 2.08M | 2.3M | 2.53M | 2.46M | |
Average inventory | 5.43M | 5.79M | 6.19M | 6.7M | 7.71M | |
Days sales outstanding | 67.09 | 82.25 | 88.34 | 78.6 | 50.6 | |
Days payables outstanding | 77.06 | 72.51 | 96.25 | 115.67 | 113.1 | |
Days of inventory on hand | 228.8 | 190.97 | 265.39 | 295.01 | 441.7 | |
Receivables turnover | 1.34 | 1.09 | 1.02 | 1.15 | 1.78 | |
Payables turnover | 1.17 | 1.24 | 0.94 | 0.78 | 0.8 | |
Inventory turnover | 0.39 | 0.47 | 0.34 | 0.31 | 0.2 | |
ROE | -0.06 | 0.03 | -0.02 | 0 | -0.04 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
LJPC Frequently Asked Questions
What is La Jolla Pharmaceutical Company stock symbol ?
La Jolla Pharmaceutical Company is a US stock , located in San diego of California and trading under the symbol LJPC
What is La Jolla Pharmaceutical Company stock quote today ?
La Jolla Pharmaceutical Company stock price is $- today.
Is La Jolla Pharmaceutical Company stock public?
Yes, La Jolla Pharmaceutical Company is a publicly traded company.